The historical rank and industry rank for TransMedics Group's ROE % or its related term are showing as below:
HAM:8T8'
s ROE % Range Over the Past 10 Years
Min: -51.49 Med: -21.91 Max: 54.24
Current: 45.08
During the past 10 years, TransMedics Group's highest ROE % was 54.24%. The lowest was -51.49%. And the median was -21.91%.
HAM:8T8's ROE % is ranked better than 97.74% of 797
companies
in the Medical Devices & Instruments industry
Industry Median: 2.4
vs HAM:8T8: 45.08
TransMedics Group (HAM:8T8) ROE % Explanation
ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.
The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:
Note:
The net income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net Income is used.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.
TransMedics Group ROE % Related Terms
TransMedics Group ROE % Historical Data
* Premium members only.
The historical data trend for TransMedics Group's ROE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, TransMedics Group's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
TransMedics Group ROE % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, TransMedics Group's ROE % distribution charts can be found below:
* The bar in red indicates where TransMedics Group's ROE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
ROE % is displayed in the 30-year financial page.
TransMedics Group (HAM:8T8) has a ROE % of 6.09% as of Mar. 2026. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on TransMedics Group and its competitors. According to the industry distribution chart, TransMedics Group ranks #18 out of 797 companies in the Medical Devices & Instruments industry, placing it in the top 2.3%.
Is TransMedics Group's ROE % too high?
TransMedics Group's current ROE % is 6.09%. The Medical Devices & Instruments industry median ROE % is 2.40. TransMedics Group's value of 6.09% is 153.8% above this industry median. Based on the distribution chart, TransMedics Group ranks #18 out of 797 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, TransMedics Group has a GF Score™ of 69/100, reflecting its overall financial health beyond just this single metric.
How does TransMedics Group's ROE % compare to AXGN and BFLY?
According to the Medical Devices & Instruments industry distribution chart, TransMedics Group ranks #18 out of 797 companies for ROE %. This places TransMedics Group in the top 2% of its industry — outperforming the majority of peers. The industry median ROE % is 2.40. TransMedics Group's value of 6.09% is 153.8% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Medical Devices & Instruments company?
The median ROE % among Medical Devices & Instruments companies is 2.40, based on 797 companies in the industry. Companies in the top quartile (top 25%) have a ROE % significantly above this median, while those in the bottom quartile fall well below. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. TransMedics Group's current ROE % of 6.09% is 153.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on TransMedics Group and its competitors. For the Medical Devices & Instruments industry, the median ROE % is 2.40 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. TransMedics Group's current ROE % is 6.09%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TransMedics Group stock overvalued right now?
TransMedics Group (HAM:8T8) has a current ROE % of 6.09%. The stock's GF Value™ is €162.08, compared to a current price of €60.02 — trading 63% below its estimated fair value. The current ROE % is 6.09% and 153.8% above the Medical Devices & Instruments industry median of 2.40. TransMedics Group's overall GF Score™ is 69/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For TransMedics Group (HAM:8T8), the current ROE % is 6.09% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is TransMedics Group (HAM:8T8) Overvalued in 2026?
Based on GuruFocus' analysis, TransMedics Group stock appears to be undervalued.
The current stock price of €60.02 is trading 63% below its estimated GF Value™ of €162.08.
Key valuation signals for HAM:8T8:
ROE %: 6.09%
GF Value™: €162.08 vs. price of €60.02 (63% below fair value)
Industry Position: 153.8% above the Medical Devices & Instruments median (#18 of 797)
No single metric tells the full story. See the HAM:8T8 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System (OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization, and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.
69GF Score
Get the complete analysis for HAM:8T8
ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HAM:8T8 has been successfully added to your 
